Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
J Urol. 2010 Mar;183(3):862-69. doi: 10.1016/j.juro.2009.11.019. Epub 2010 Jan 18.
The number of centers performing robotic assisted radical cystectomy has recently increased, spurring greater concerns about oncological outcomes. In this review we summarize the most comprehensive articles published on the oncological outcomes of laparoscopic assisted, robotic assisted and open radical cystectomy.
A MEDLINE/PubMed literature search was conducted in March 2009 to review English language articles published from 1998 onward. Of 217 selected articles on the 3 techniques 19 studies were selected for this review.
The laparoscopic series reported recurrence-free survival rates in the range of 83% to 85% at 1 to 2 years and 60% to 77% at 2 to 3 years, while the robotic assisted studies reported recurrence-free survival rates of 86% to 91% at 1 to 2 years. Large open surgery studies showed 62% to 68% recurrence-free survival at 5 years and 50% to 60% at 10 years, with overall survival of 59% to 66% at 5 years and 37% to 43% at 10 years. Overall survival in the laparoscopic cohorts was 90% to 100% at 1 to 2 years and 50% to 87% at 2 to 3 years. Publications reporting robotic cases demonstrated a 90% to 96% overall survival in 1 to 2 years of followup.
Despite the surge of centers adopting minimally invasive approaches for radical cystectomy, the long-term effectiveness of these techniques has not yet been proven. This review of recent and landmark articles on open and minimally invasive procedures emphasizes the need for prospective controlled studies and long-term followup data to determine the proper use of laparoscopic and robotic assisted techniques in bladder cancer surgery.
最近施行机器人辅助根治性膀胱切除术的中心数量有所增加,由此引发了人们对肿瘤学结果的更多关注。在这篇综述中,我们总结了发表于腹腔镜辅助、机器人辅助和开放性根治性膀胱切除术的肿瘤学结果的最全面的文章。
2009 年 3 月,我们通过 MEDLINE/PubMed 文献检索,查阅了自 1998 年以来发表的英文文章。在 217 篇关于这 3 种技术的文章中,有 19 篇被纳入本综述。
腹腔镜系列报道的 1 至 2 年无复发生存率为 83%至 85%,2 至 3 年为 60%至 77%,而机器人辅助研究报道的 1 至 2 年无复发生存率为 86%至 91%。大型开放性手术研究显示,5 年时无复发生存率为 62%至 68%,10 年时为 50%至 60%,5 年时总体生存率为 59%至 66%,10 年时为 37%至 43%。腹腔镜队列的 1 至 2 年总体生存率为 90%至 100%,2 至 3 年为 50%至 87%。报道机器人病例的出版物显示,1 至 2 年的总体生存率为 90%至 96%。
尽管越来越多的中心采用微创方法施行根治性膀胱切除术,但这些技术的长期效果尚未得到证实。本综述对开放性和微创性手术的最新和具有里程碑意义的文章进行了回顾,强调需要前瞻性对照研究和长期随访数据,以确定腹腔镜和机器人辅助技术在膀胱癌手术中的正确应用。